Navigation Links
Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
Date:10/15/2008

BOULDER, Colo., Oct. 15 /PRNewswire/ -- Bolder BioTechnology, Inc. announced today that it has been awarded a $1.6 million Phase II Continuing Renewal Small Business Innovation Research (SBIR) grant, entitled "Long-Acting Beta Interferon for Multiple Sclerosis", from the National Institute of Neurological Disorders and Stroke (NINDS) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.

George (Joe) Cox, Ph.D., Company President and Principal Investigator for the grant, stated, "We are grateful to receive continued support from NINDS for our long-acting beta interferon program. With previous funding from NINDS we developed a novel beta interferon analog that has a longer duration of action and more potent biological activity than existing beta interferon products in animals. The new grant award will be used to perform preclinical studies required by the Food and Drug Administration for filing an Investigational New Drug application to begin testing our long-acting beta interferon analog in people. Recombinant beta interferon products have annual worldwide sales of approximately $5 billion, primarily from use of the drugs to treat Multiple Sclerosis. Multiple Sclerosis is a debilitating neurological disease that affects approximately 400,000 people in the United States and 2.5 million people worldwide. Current commercial beta interferon products are only partially effective and are inconvenient to use because they must be injected frequently, typically for the life of the patient. Our long-acting beta interferon analog was designed to provide patients with a more efficacious and easier to use product."

The NIH SBIR program is a peer-reviewed grant program that provides research support to small businesses to discover and develop innovative biomedical products for the treatment of serious unmet medical needs.

Bolder BioTechnology, Inc. uses advanced p
'/>"/>

SOURCE Bolder BioTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. New White Paper Details Strategies for Biotechnology Companies to Improve EH&S Compliance
3. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
4. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
5. Luminex Corporation to Present at Biotechnology Industry Organization Investor Forum
6. An Uncommon Eye: Photography Exhibit by Biotechnology Executive at BHCC Gallery
7. Onyx Pharmaceuticals to Present at Biotechnology Industry Organization Investor Forum
8. Leading Biotechnology Company Grows with StayinFront CRM
9. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
10. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
11. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Experts and industry insiders from around ... the Alltech REBELation exploring innovation, inspiration and world-changing ideas ... its 31st year, Alltech’s annual international conference traditionally draws ... opportunity to join the REBELation at an extra discount ... EST, at which point the standard early registration rate ...
(Date:3/3/2015)... 3, 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), a life ... and products for advanced microarray diagnostics, today announced ...  to its Management team. In his capacity as ... transition from a development stage to a commercially ... the Company,s capital market strategy and to secure ...
(Date:3/3/2015)...  Regenicin, Inc. (OTC Bulletin Board: RGIN ... and commercialization of regenerative cell therapies to restore the ... it has received the final payment to conclude The ... Bulletin Board: AMBS ). ... payments due to Regenicin in the amount of $2.3 ...
(Date:3/3/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... Expert Opinion on Biological Therapy , Dr. ... Zhang , at the Henry Ford Hospital in ... 4 (TB4) has the capacity to promote CNS and ... post-injury, leading to neurological recovery in each case.  They ...
Breaking Biology Technology:World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... 2011 Biotechnology leader Divine Skin Inc. (DSKX) posted ... quarter. The expanding innovator of personal care solutions credits ... sales, which are 79 percent ahead of the same ... has been keeping up with demand," said Divine Skin ...
... FMC Corporation (NYSE: FMC ) announced ... exclusive agreements covering global development and supply of Chr. ... will begin commercialization this year of Chr. Hansen,s Nemix ... biological standalone and combination products in the Americas and ...
... Sureshkumar, professor and chair of biomedical and chemical ... Engineering and Computer Science, and professor of physics, ... stable suspensions of metal nanoparticles capable of capturing ... the researchers can "dial in" to a given ...
Cached Biology Technology:Divine Skin Posts Record Q2 Revenue of $2.33 Million, up 79 Percent From 2010 2Divine Skin Posts Record Q2 Revenue of $2.33 Million, up 79 Percent From 2010 3FMC Corporation Announces Exclusive Global Development and Supply Agreements for Chr. Hansen Biological Products 2Tunable nano-suspensions for light harvesting 2
(Date:2/24/2015)... -- This report analyzes the worldwide markets for Iris Biometrics ... the US, Canada , Japan ... , Middle East , and ... provided for the period 2013 through 2020. Also, a seven-year ... analytics are derived from primary and secondary research. Company profiles ...
(Date:2/18/2015)... Feb. 18, 2015  Cepheid (NASDAQ: CPHD ) ... following conferences, and invited investors to participate via webcast. ... MA Tuesday, March 3, 2015 at 11.20 a.m. ... Orlando, FL Wednesday, March 4, 2015 at ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:2/10/2015)... Feb. 10, 2015  Alere Inc. (NYSE: ALR), ... financial results for the quarter ended December 31, ... and President of Alere said, "We made substantial ... as the global leader in rapid diagnostics and ... Alere Health divestiture in early January enabled us ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Cepheid to Webcast Upcoming Financial Presentations 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25
... and doctors, not to mention the cleaning product industry, ... School of Medicine microbiologist is raising the intriguing idea ... Stanley Falkow, PhD, the Robert W. and Vivian K. ... on this topic in an essay in the Feb. ...
... Bacteria are bad. Mothers and doctors, not to mention ... But a Stanford University School of Medicine microbiologist is ... infections have benefits. , Stanley Falkow, PhD, the Robert ... is publishing his thoughts on this topic in an ...
... of Trends in Biotechnology, scientists and doctors with the ... animal serum-free media to grow live cells in the ... serum, which is obtained by puncturing the heart of ... growth of human cells in a medium free of ...
Cached Biology News:Scientists look to the Bahamas as a model for coral reef conservation 2Scientists look to the Bahamas as a model for coral reef conservation 3Learning to love bacteria: Stanford scientist highlights bugs' benefits 2Learning to love bacteria: Stanford scientist highlights bugs' benefits 3